Overview of the drug development for polymyositis
It has been observed that polymyositis is characterized by chronic muscle inflammation accompanied by muscle weakness. Polymyositis affects skeletal muscles. It mostly affects adults in the age group of 31-60 years and is rarely seen in people under 18 years of age. The condition mainly develops when an attack on muscle tissue occurs by white blood cells called T lymphocytes, which are produced by the immune system to fight infection. Furthermore, symptoms of the disease also include muscle weakness, aching or painful muscles, shortness of breath, and difficulty in swallowing and speaking, and heart arrhythmias. According to the Committee for Orphan Medicinal Products (COMP) in November 2014, polymyositis affected approximately 0.4 people in 10,000 people in the EU region. Consequently, with rising incidences of the disease, the drug development for polymyositis is expected to increase considerably during the next few years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for polymyositis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of polymyositis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Genetech
- Viela Bio
Therapeutic assessment of the drug development for polymyositis by route of administration
- Subcutaneous
- Intravenous
The subcutaneous route of administration (ROA) involves the application of the drug is delivered into the subcutis, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development for polymyositis by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, most of the molecules that are currently in the drug development for polymyositis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug molecules in the various development stages for polymyositis?
- What are the companies that are currently involved in the development of drug molecules for polymyositis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.